155 related articles for article (PubMed ID: 38482675)
1. TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma.
Brunelli M; Gobbo S; Malpeli G; Sirgiovanni G; Caserta C; Munari E; Francesconi S; Caliò A; Martignoni G; Cimadamore A; Veccia A; Antonelli A; Tucci M; Pierconti F; Hattab IM; Eccher A; Ascani S; Milella M; Buffoni L; Cheng L; Bracarda S
Pathologica; 2024 Feb; 116(1):55-61. PubMed ID: 38482675
[TBL] [Abstract][Full Text] [Related]
2. Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.
Bahlinger V; Branz A; Strissel PL; Strick R; Lange F; Geppert CI; Klümper N; Hölzel M; Wach S; Taubert H; Sikic D; Wullich B; Angeloni M; Ferrazzi F; Diehl L; Kovalenko M; Elboudwarej E; Jürgensmeier JM; Hartmann A; Eckstein M
Histopathology; 2024 Apr; 84(5):863-876. PubMed ID: 38196202
[TBL] [Abstract][Full Text] [Related]
3. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.
Ghali F; Vakar-Lopez F; Roudier MP; Garcia J; Arora S; Cheng HH; Schweizer MT; Haffner MC; Lee JK; Yu EY; Grivas P; Montgomery B; Hsieh AC; Wright JL; Lam HM
Clin Genitourin Cancer; 2023 Dec; 21(6):669-678. PubMed ID: 37344281
[TBL] [Abstract][Full Text] [Related]
4. The utility of fluorescence in situ hybridization for detection of bladder urothelial carcinoma in routine clinical practice.
Kwak KW; Kim SH; Lee HM
J Korean Med Sci; 2009 Dec; 24(6):1139-44. PubMed ID: 19949672
[TBL] [Abstract][Full Text] [Related]
5. The utility of fluorescence in situ hybridization for diagnosis and surveillance of bladder urothelial carcinoma.
Huang JW; Mu JG; Li YW; Gan XG; Song LJ; Gu BJ; Fu Q; Xu YM; An RH
Urol J; 2014 Nov; 11(6):1974-9. PubMed ID: 25433477
[TBL] [Abstract][Full Text] [Related]
6. Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes.
Hoffman-Censits JH; Lombardo KA; Parimi V; Kamanda S; Choi W; Hahn NM; McConkey DJ; McGuire BM; Bivalacqua TJ; Kates M; Matoso A
Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):619-625. PubMed ID: 33901032
[TBL] [Abstract][Full Text] [Related]
7. GATA3 expression in sarcomatoid urothelial carcinoma of the bladder.
Fatima N; Osunkoya AO
Hum Pathol; 2014 Aug; 45(8):1625-9. PubMed ID: 24824028
[TBL] [Abstract][Full Text] [Related]
8. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.
Wong JL; Rosenberg JE
Expert Opin Biol Ther; 2021 Jul; 21(7):863-873. PubMed ID: 34030536
[TBL] [Abstract][Full Text] [Related]
9. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma.
Brunelli M; Tafuri A; Cima L; Cerruto MA; Milella M; Zivi A; Buti S; Bersanelli M; Fornarini G; Vellone VG; Rebuzzi SE; Procopio G; Verzoni E; Bracarda S; Sabbatini R; Baldessari C; Eccher A; Passalacqua R; Perrucci B; Giganti MO; Donini M; Panni S; Tucci M; Prati V; Ortega C; Caliò A; Alongi F; Munari E; Pappagallo G; Iacovelli R; Mosca A; Porta C; Martignoni G; Antonelli A
J Clin Pathol; 2022 Jan; 75(1):39-44. PubMed ID: 33144356
[TBL] [Abstract][Full Text] [Related]
10. TROP-2, Nectin-4, GPNMB, and B7-H3 Are Potentially Therapeutic Targets for Anaplastic Thyroid Carcinoma.
Toda S; Sato S; Saito N; Sekihara K; Matsui A; Murayama D; Nakayama H; Suganuma N; Okubo Y; Hayashi H; Iwasaki H; Miyagi Y; Hoshino D
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158847
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer.
Wucherpfennig S; Rose M; Maurer A; Cassataro MA; Seillier L; Morsch R; Hammad E; Baldia PH; Ecke TH; Vögeli TA; Knüchel R; Gaisa NT
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768978
[TBL] [Abstract][Full Text] [Related]
12. α4 contributes to bladder urothelial carcinoma cell invasion and/or metastasis via regulation of E-cadherin and is a predictor of outcome in bladder urothelial carcinoma patients.
Liu J; Cai M; Chen J; Liao Y; Mai S; Li Y; Huang X; Liu Y; Zhang J; Kung H; Zeng Y; Zhou F; Xie D
Eur J Cancer; 2014 Mar; 50(4):840-51. PubMed ID: 24388773
[TBL] [Abstract][Full Text] [Related]
13. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma.
Petros FG; Choi W; Qi Y; Moss T; Li R; Su X; Guo CC; Czerniak B; Dinney C; McConkey DJ; Matin SF
J Urol; 2021 Sep; 206(3):548-557. PubMed ID: 33881933
[TBL] [Abstract][Full Text] [Related]
14. MLKL and other necroptosis-related genes promote the tumor immune cell infiltration, guiding for the administration of immunotherapy in bladder urothelial carcinoma.
Zhong B; Wang Y; Liao Y; Liang J; Wang K; Zhou D; Zhao Y; Jiang N
Apoptosis; 2023 Jun; 28(5-6):892-911. PubMed ID: 37000317
[TBL] [Abstract][Full Text] [Related]
15. Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma.
Tekin B; Cheville JC; Herrera Hernandez L; Negron V; Smith CY; Jenkins SM; Dasari S; Enninga EAL; Norgan AP; Menon S; Cubilla AL; Whaley RD; Jimenez RE; Thompson RH; Leibovich BC; Karnes RJ; Boorjian SA; Pagliaro LC; Erickson LA; Guo R; Gupta S
Hum Pathol; 2023 Dec; 142():42-50. PubMed ID: 37977513
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer.
Abbas M; Heitplatz B; Bernemann C; Boegemann M; Trautmann M; Schrader AJ; Wardelmann E; Schlack K
Oncol Lett; 2023 Dec; 26(6):527. PubMed ID: 38020299
[TBL] [Abstract][Full Text] [Related]
18. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y
Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of urine cyclic RNA-0071196 for bladder urothelial carcinoma.
Yang Y; Li J; Yao W; Zou G; Ye X; Mo Q
BMC Urol; 2024 Apr; 24(1):88. PubMed ID: 38627689
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study.
Paliogiannis P; Lobrano R; Bella MA; Fara A; Uras MG; Pinna MA; Tedde A; Madonia M; Zinellu A; Cossu A
Ann Diagn Pathol; 2024 Apr; 69():152267. PubMed ID: 38266544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
